Performed statistical analysis on over a hundred cases of tumors or other lesions to show significant relationships. Currently available technology, including array comparative genomic hybridization as well as fluorescence in-situ hybridization and immunostaining, allows a deeper understanding for diagnosis and for classification. Sorting out these issues often has a direct and immediate relationship to prognosis and clinical management, such as with oligodendrogliomas and their chromosomal deletion status. Newly emerging brain tumor entities are being understood by use of the available technology. Laboratory methods help to show differences of emerging entities from current classification but also similarities so that some of these “new” tumors can be understood as subcategories of traditional tumors. Therefore, cutting edge tumor analysis in the laboratory translates into the most appropriate diagnosis from which clinical management is planned. Clinical and laboratory information that together suggest a category for a “non-traditional” brain tumor will go beyond the “malignant glioma” moniker for increasing numbers of patients and this information requires sophisticated new laboratory methods now under development.